December 30, 2020

Phibro to market Virbac's TULISSIN^® 100 in Canada

Virbac and Phibro Animal Health have entered into an agreement under which Phibro will represent and market Virbac's newly approved TULISSIN 100 brand of tulathromycin antibiotic, according to a press statement.

Virbac has received approval from Health Canada for TULISSIN 100, which is indicated for use in cattle, swine and sheep.

TULISSIN 100 supports Canadian cattle and swine producer herd health protocols, and is an addition to Phibro's portfolio of ruminant and swine products including V-Max®, Neo-Terramycin®, Terramycin®, Stafac® and PRO-Banminth®. TULISSIN 100 helps producers treat disease and reduce death loss associated with respiratory disease.

TULISSIN 100 will be available beginning in January 2021. More information is available from local Phibro representatives.